In the following subparagraphs, we summarize the studies that demonstrated that AIM2 has an anti-tumor function in colon, colorectal and breast cancer, melanoma, hepatocellular carcinoma, bladder cancer, osteosarcoma, and brain tumors (Figure 2). This evidence concerns the gene AIM2 and melanoma.